Deputy President David Mabuza. (Jan Gerber/News24) Deputy President David Mabuza has commended Public Works and Infrastructure Minister Patricia de Lille's efforts to root out corruption in her department.Mabuza said the government has taken several measures to ensure money meant for infrastructure projects are spent correctly.He was answering questions in the National Council of Provinces on…
PARIS/LONDON/MILAN (Reuters) - European governments moved on Wednesday to halt the use of anti-malaria drug hydroxychloroquine to treat COVID-19 patients, and a second global trial was suspended, further blows to hopes for a treatment promoted by U.S. President Donald Trump. The moves by France, Italy and Belgium followed a World Health Organization decision on Monday…
UCT reveals first group of students who will be allowed back, but no dates confirmed yetStudents in all years of study that require clinical training in their programmes can also go back. Universities can also decide to allow back students to residences who may face "extreme difficulties" in learning at home.Once Level 3 is announced,…
once-off allowance to move between provinces, should they need to move "to the provinces where they are employed".But the DA believes if government had used its proposed smart lockdown proposal, more of the economy could have been opened without compromising safety."Ultimately, there is not enough to distinguish lockdown Level 4 from Level 5. This will…
The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment
Millions of Medicare enrollees who buy stand-alone prescription drug plans will see their average monthly premiums rise by 50% in 2027, a new analysis finds. But enrollees can avoid the average increase — from $34 a month to $51 — by switching to lower-cost plans during the program’s open enrollment period, which runs through Dec.
You don't have permission to access "http://www.medpagetoday.com/washington-watch/washington-watch/123652" on this server. Reference #18.d494d817.1793332899.22e6a54f https://errors.edgesuite.net/18.d494d817.1793332899.22e6a54f